ABSTRACT
Background We previously investigated the association between five ‘first-generation’ measures of epigenetic aging and cancer risk in the Melbourne Collaborative Cohort Study. The present study assessed cancer risk associations for three recently developed methylation-based biomarkers of aging: PhenoAge, GrimAge, and predicted telomere length.
Methods We estimated rate ratios (RRs) for the association between these three age-adjusted measures and risk of colorectal (N=813), gastric (N=165), kidney (N=139), lung (N=327), mature B-cell (N=423), prostate (N=846) and urothelial (N=404) cancer, using conditional logistic regression models. We also assessed associations by time since blood draw and by cancer subtype, and investigated potential non-linearity.
Results We observed relatively strong associations of age-adjusted PhenoAge with risk of colorectal, kidney, lung, mature B-cell, and urothelial cancers (RR per standard deviation [SD]∼1.2-1.3). Similar findings were obtained for age-adjusted GrimAge, but the association with lung cancer risk was much larger, RR per SD=1.82, 95%CI=1.44-2.30, after adjustment for smoking status, pack-years, starting age, time since quitting and other cancer risk factors. Most associations appeared linear, larger than for the first-generation measures, and were virtually unchanged after adjustment for a large set of sociodemographic, lifestyle and anthropometric variables. For cancer overall, the comprehensively-adjusted RR per SD was 1.13, 95%CI=1.07-1.19, for PhenoAge and 1.12, 95%CI=1.05-1.20, for GrimAge, and appeared larger within 5 years of blood draw (RR=1.29 and 1.19, respectively).
Conclusion The methylation-based measures PhenoAge and GrimAge may provide insights into the relationship between biological aging and cancer and be useful to predict cancer risk, particularly for lung cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Australian National Health and Medical Research Council (NHMRC) grants 1164455. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The nested case-control methylation studies were supported by the NHMRC grants 1011618, 1026892, 1027505, 1050198, 1043616 and 1074383. M.C.S. is an NHMRC Senior Research Fellow (1061177). This work also received funding from Monash University, Melbourne, Australia.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
- changed from a brief report to a full article - several additional analyses: associations by time since blood draw, non-linearity of associations, and additional adjustments - augmented Discussion section
Data Availability
The data that support the findings of this study are available from the corresponding author, PAD, upon reasonable request.
